Abstract:Malignant gliomas are the most common (60–70%) of all CNS/brain tumors. Annually, thereare approximately five cases of malignant gliomas per 100,000 people, and over 14,000 newcases are diagnosed each year in the United States (1,2). Surgery remains the standard therapyfor primary brain tumors. Although surgery may be combined with radiation therapy and/orfollowed with chemotherapy to destroy remaining cancer cells, patients still have a poorsurvival (3-5). In recent years, Temozolomide (TMZ, Temodar®), a prodrug which undergoesspontaneous conversion to the active alkylating agent (Charts 1 and 2) has emerged as a potentchemotherapeutic agent (6). In combination with radiotherapy, it has been shown tosubstantially increase median survival compared with radiotherapy alone (7). However, TMZhas considerable toxicity, which prevents therapeutic dosage increase. Moreover, anotherlimiting factor of TMZ treatment is tumor resistance to the drug (8-10).Recently, efforts have been made to develop delivery systems for conventionalchemotherapeutic drugs. Polymer-based delivery systems are less immunogenic than proteinbased,e.g. viral vectors, and allow repetitive treatments without acute or chronic host immuneresponse (11-14). Compared with most chemotherapeutic molecules, macromolecules offerseveral advantages, including tumor targeting, increased solubility, enhanced accumulation insolid tumors, decreased general toxicity, increased maximum tolerated doses, circumventionof multidrug resistance and enhanced apoptosis induction (15,16). Nanodrugs can selectivelyaccumulate in tumor through a passive targeting mechanism known as enhanced permeabilityand retention (EPR) effect (17-19). Targeting efficiency is substantially enhanced bycombining nanodrugs with specific antibodies that allow targeting by binding to antigens onthe tumor cell surface (20-22).To avoid systemic side effects by orally administered TMZ, targeting to brain tumor would behighly important. Recently, Brem (23) and Akbar (24) have administered a solid mixture ofbiodegradable polymer and TMZ directly into the brain tumor in animal models. The drug wasprogressively released during degradation of the embedding polymer material and significantlyprolonged the survival time of experimental animals. These methods are invasive, and the drugis applied at the time of surgery. Moreover, gliomas are tumors with the ability to developrecurrences; thus, systemic and targeted delivery of TMZ would be a more beneficial treatmentapproach.Following I.V. administration, we have delivered antisense oligonucleotides specifically tobrain tumor using the targeted nanoconjugate delivery system, Polycefin (21). Thenanoconjugate platform, poly(β-L-malic acid) (PMLA), is biodegradable, non-toxic and nonimmunogenic,containing numerous pendant carboxyl groups suitable for the covalentattachment of prodrugs and other useful molecules. For the delivery into the cytoplasm ofrecipient glioma cells, we conjugated TMZ in its hydrazide form with PMLA along with antitransferrinreceptor (TfR) monoclonal antibody (mAb) for tumor targeting by receptormediatedendocytosis (21) and pH-sensitive trileucine (LLL) for disruption of endosomalmembranes.

Development and characterization of temozolomide-PAMAM-siRNA dendriplexes for the effective management of glioblastoma multiforme

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide

Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma

Use of surface-modified porous silicon nanoparticles to deliver temozolomide with enhanced pharmacokinetic and therapeutic efficacy for intracranial glioblastoma in mice

PLGA-based dual-loaded nanoformulation of DIM and TMZ - An advanced clinical strategy for brain cancer treatment in a combinatorial approach

Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide: In Vitro and In Vivo Effects of PEGylation in the Management of Glioblastoma Multiforme

Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ

Glioblastoma Multiforme: Probing Solutions to Systemic Toxicity towards High-Dose Chemotherapy and Inflammatory Influence in Resistance against Temozolomide

Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies

Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study

Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation

Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy

A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co‐Delivery of Temozolomide and a Methylguanine‐DNA Methyltransferase Inhibitor

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma

Increased the TMZ concentration in brain by poly(2-ethyl-2-oxazoline) conjugated temozolomide prodrug micelles for glioblastoma treatment

Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma

Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid)

Polydopamine-based loaded temozolomide nanoparticles conjugated by peptide-1 for glioblastoma chemotherapy and photothermal therapy

Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy

A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation